Pheochromocytoma

M. J. Brown; A. B. Grossman; S. R. Bornstein

doi:10.1055/s-0029-1238311

Hormone and Metabolic Research, Table of Contents

Horm Metab Res 2009; 41(9): 655-657
DOI: 10.1055/s-0029-1238311

Editorial

Pheochromocytoma

M. J. Brown¹ , A. B. Grossman² , S. R. Bornstein³

¹Clinical Pharmacology Unit, University of Cambridge, Cambridge, UK
²Department of Endocrinology, Barts and the London School of Medicine, London, UK
³Endocrinology, Diabetes and Metabolism, Department of Medicine, Carl Gustav Carus, University of Dresden, Dresden, Germany

Abstract

Full Text

References

1 Qin Y, Buddavarapu K, Dahia PL. Pheochromocytomas: from genetic diversity to new paradigms. Horm Metab Res. 2009; 41 664-671
2 Cascón A, López-Jiménez E, Landa I, Leskelä S, Leandro-García LJ, Maliszewska A, Letón R, Vega LD, García-Barcina MJ, Sanabria C, Alvarez-Escolá C, Rodríguez-Antona C, Robledo M. Rationalization of genetic testing in patients with apparently sporadic pheochromocytoma/paraganglioma. Horm Metab Res. 2009; 41 672-675
3 Brown MJ. Simultaneous assay of noradrenaline and its deaminated metabolite, dihydroxyphenylglycol, in plasma: a simplified approach to the exclusion of pheochromocytoma in patients with borderline elevation of plasma noradrenaline concentration. Eur J Clin Invest. 1984; 14 67-72
4 Unger N, Deutschbein T, Walz MK, Mann K, Petersenn S. The value of immunoassays for metanephrines in the biochemical diagnosis of pheochromocytomas. Horm Metab Res. 2009; 41 676-679
5 Carlsen E, Abdullah Z, Kazmi SM, Kousparos G. Pheochromocyto-mas, PASS, and immunohistochemistry. Horm Metab Res. 2009; 41 715-719
6 Papewalis C, Kouatchoua C, Wuttke M, Jacobs B, Scherbaum WA, Schott M. Chromogranin A as potential tumour antigen in pheochromocytoma. Horm Metab Res. 2009; 41 707-709
7 Powers JF, Picard KL, Tischler AS. RET expression and neuron-like differentiation of pheochromocytoma and normal chromaffin cells. Horm Metab Res. 2009; 41 710-714
8 Santarpia L, Habra MA, Jiménez C. Malignant pheochromocytomas and paragangliomas: molecular signaling pathways and emerging therapies. Horm Metab Res. 2009; 41 680-686
9 Adjallé R, Plouin PF, Pacak K, Lehnert H. Treatment of malignant pheochromocytoma. Horm Metab Res. 2009; 41 687-696
10 Druce MR, Kaltsas GA, Fraenkel M, Gross DJ, Grossman AB. Novel and evolving therapies in the treatment of malignant pheochromocytoma: experience with the mTOR Inhibitor everolimus (RAD001). Horm Metab Res. 2009; 41 697-702
11 Bravo EL, Kalmadi SR, Gill I. Clinical utility of temozolomide in the treatment of malignant paraganglioma: a preliminary report. Horm Metab Res. 2009; 41 703-706
12 Manger WM. The protean manifestations of pheochromocytoma. Horm Metab Res. 2009; 41 658-663

Correspondence

Prof. M. J. Brown

Clinical Pharmacology Unit University of Cambridge Addenbrookes Centre for Clinical Investigation (ACCI)

Level 6 Addenbrookes Hospital, Box 110

Cambridge CB2 2QQ

UK

Phone: +44/1223/33 67 43

Fax: +44/1223/76 25 76

Email: mjb14@hermes.cam.ac.uk

Prof. A. B. Grossman

Department of Endocrinology

St. Bartholomew's Hospital

West Smithfield

London EC1A 7BE

UK

Phone: +44/20/7601 83 43

Fax: +44/20/7601 85 05

Email: a.b.grossman@qmul.ac.uk